Wedbush Downgrades Aerovate Therapeutics to Neutral From Outperform, Adjusts Price Target to $3 From $41
Wedbush Downgrades Aerovate Therapeutics to Neutral From Outperform, Adjusts Price Target to $3 From $41
Wedbush将Aerovate Therapeutics的评级从Outperform下调至中立，将目标价从41美元调整为3美元。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册
资讯热榜
更新时间